<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317248</url>
  </required_header>
  <id_info>
    <org_study_id>2019B110233002</org_study_id>
    <nct_id>NCT04317248</nct_id>
  </id_info>
  <brief_title>&quot;Cocktail&quot; Therapy for Hepatitis B Related Hepatocellular Carcinoma</brief_title>
  <official_title>Precision Study on &quot;Cocktail&quot; Therapy to Improve the Efficacy of Hepatitis B-related Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuehua Huang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of anti-tumor treatment is not satisfying in HBV-related hepatocellular carcinoma
      (HBV-HCC) for reasons that HBV-HCC carries highly heterogeneous antigens to facilitate cancer
      cells escaping from immune surveillance and constructs an immunosuppressive microenvironment.
      Correspondingly, multiple signals loaded dendritic cells vaccine can efficiently present T
      cells with antigens of HCC sensitize their antitumor properties meanwhile low dose
      cyclophosphamide (CY) can effectively improve the microenvironment of immunity. Therefore, we
      put forward a new scientific therapy called &quot;multiple signals loaded dendritic cells vaccine
      combined low dose of cyclophosphamide&quot; combining with radical surgery or TACE or targeted
      agents for patients with hepatocellular carcinoma to prolong their survival time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description Patients who have good compliance complying with the inclusion criteria
      will be enrolled into our research. The 600 patients will be randomly assigned to
      experimental group and control group with the ratio of 1:1, control group will receive
      radical surgery or TACE or targeted agent treatment solely; another group (experimental
      group) after enrollment will radical surgery or TACE or targeted agent treatment in the first
      course. Then 20ml blood is taken for multiple signals loaded dendritic cells (MSDCV) culture
      (cell culture takes 7 days). Low dose (250mg/m^2) CY treatment will be performed on patients
      two days before the MSDCV treatment. The MSDCV combined CY therapy will perform per 4 weeks,
      total 6 times. All patients are evaluated the safety and efficacy of treatment by monitoring
      their blood parameters, tumor indicators and imaging examinations at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free-Survival (PFS), month</measure>
    <time_frame>240 weeks</time_frame>
    <description>The time from randomization until first documented progression or death from any cause，whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum AFP(alpha fetoprotein）, ng/ml</measure>
    <time_frame>240 weeks</time_frame>
    <description>Measured for each subjects at each visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum PIVKA-II(Protein Induced by Vitamin K Absence or Antagonist-II), μg/L</measure>
    <time_frame>240 weeks</time_frame>
    <description>Measured for each subjects at each visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS), month</measure>
    <time_frame>240 weeks</time_frame>
    <description>The time from random assignment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor size, mm</measure>
    <time_frame>240 weeks</time_frame>
    <description>Utilizing Liver CT or MR examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>240 weeks</time_frame>
    <description>Assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>MSDCV immune therapy combined with radical surgery therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time before the first time of MSDCV immune therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical surgery therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hepatocellular Carcinoma Radical surgery therapy: one time at a good operation time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDCV immune therapy combined with TACE therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: the first time of TACE therapy must perform before the first time of MSDCV immune therapy， then perform when necessary according to subjects condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Transcatheter Hepatic Arterial Chemoembolization (TACE) therapy: perform when necessary according to Subjects condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSDCV immune therapy combined with targeted agents therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Signals loaded Dendritic Cells Vaccine(MSDCV) immune therapy：one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, total 6 times; Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted agents therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Targeted agents therapy: Sorafenib or Lenvatinib. For Sorafenib: 0.4g twice daily; for Lenvatinib: 12mg/8mg per day according to subjects condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Intravenous drip，250mg/m^2 per time，two days before each times of MSDCV therapy，total 6 times, in order to improve the immunosuppressive microenvironment of tumor，reduce CD4+CD25+FOXP3+regulatory T cells (Tregs）</description>
    <arm_group_label>MSDCV immune therapy combined with TACE therapy</arm_group_label>
    <arm_group_label>MSDCV immune therapy combined with radical surgery therapy</arm_group_label>
    <arm_group_label>MSDCV immune therapy combined with targeted agents therapy</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multiple Signals loaded Dendritic Cells Vaccine</intervention_name>
    <description>one time every 4 weeks during 0 weeks to 20 weeks, about 5*10^7 cells per time, intravenous driptotal 6 times;</description>
    <arm_group_label>MSDCV immune therapy combined with TACE therapy</arm_group_label>
    <arm_group_label>MSDCV immune therapy combined with radical surgery therapy</arm_group_label>
    <arm_group_label>MSDCV immune therapy combined with targeted agents therapy</arm_group_label>
    <other_name>MSDCV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In accordance with AASLD guidelines for the diagnosis of hepatocellular
             carcinoma，histology or imaging confirmed as primary hepatocellular carcinoma

          -  Patients with history of hepatitis B infection

          -  Male and female adult subjects (18～70 years old)

          -  Patients haven't received radiation therapy or chemotherapy or immunotherapy

          -  Normal renal function

          -  Blood routine test: Hb&gt;=9g/dL, white cell count&gt;=1.5*10^9/L, platelet count&gt;=50*10^9/L

          -  Liver function: bilirubin&lt;=50umol/L, aspartate aminotransferase (AST) or alanine
             aminotransferase(ALT)&lt;=5 times the upper limit of normal

          -  Child-Pugh score&lt;=9

          -  Human Chorionic Gonadotropin(HCG) test negative(-) if patients are women of
             reproductive ages

          -  Women of reproductive ages promise to contracept until therapy course has been
             finished for 3 months

          -  Patients who have signed up informed consents

        Exclusion Criteria:

          -  Extrahepatic metastasis of hepatocellular carcinoma oHistory of embolism, chemotherapy
             or radiation

          -  History of major surgery in last 4 weeks

          -  History of radiofrequency ablation in last 6 weeks

          -  Acute infections in last 2 weeks

          -  Child-Pugh scores&gt;9

          -  Patients with hepatic encephalopathy

          -  Patients with ascites needed drainage

          -  Patients have history of other cancer

          -  Patients have history of HIV

          -  Pregnant women

          -  Patients with severe diseases like cardiac dysfunction

          -  Patients with mental illness that influence signing informed consents

          -  HBV infection combined with other types of hepatitis

          -  Patients with autoimmune diseases

          -  Immunosuppressant drugs users

          -  Patients cannot follow our trial principle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuehua Huang, doctorate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuehua HYuang, doctorate</last_name>
    <phone>0086-13822232795</phone>
    <email>huangyh53@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yifan Lian, doctorate</last_name>
    <phone>0086-13824441190</phone>
    <email>lianyf@mail3.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Liu, doctorate</last_name>
      <phone>0086-18602062738</phone>
      <email>fimmu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ming Shi, doctorate</last_name>
      <phone>0086-13925006889</phone>
      <email>shiming@sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiajun Zhang, doctorate</last_name>
      <phone>0086-13751725506</phone>
      <email>zhjiajun@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Zhongshan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhua Bi</last_name>
      <phone>0086-13829710921</phone>
      <email>821771928@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yuehua Huang</investigator_full_name>
    <investigator_title>Laboratory director of hepatology，Deputy director of infection</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>Dendritic cells vaccine</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

